For comments, suggestions
Created with Raphaël 2.1.0 18.04.2017 Filing date 16.11.2018 Validation fee payment 31.03.2019 (A1) Patent application published 30.05.2024 AGEPI application filing date 31.07.2024 (T2) Translation of the validated European patent 06.06.2025 18.04.2026 Valid until 19.04.2027 Renewal fee to be paid until 18.04.2037 Patent will expire on

Patent in force


(210)Number of the EPO application17727373
(220)Filing date of the EPO application2017.04.18
(80)EPO patent specification publication (B)EPB nr. 16/2024, 2024.04.17
(110)EPO patent number3445388
(11)Number of the documentMD 3445388 T2
(21)Number of the applicatione 2019 0261
(71)Name(s) of applicant(s), code of the countryVERTEX PHARMACEUTICALS INCORPORATED, US;
(72)Name(s) of inventor(s), code of the countryCOWAN Chad Albert, US;
LUNDBERG Ante Sven, US;
CHAKRABORTY Tirtha, US;
LIN Michelle I-ching, US;
MISHRA Bibhu Prasad, US;
PAIK Elizabeth Jae-eun, US;
KERNYTSKY Andrew, US;
BORLAND Todd Douglass, US;
(73)Name(s) of owner(s), code of the countryVERTEX PHARMACEUTICALS INCORPORATED, US;
(54)Title of the inventionMaterials and methods for treatment of hemoglobinopathies
(13)Kind-of-document code T2
(51)International Patent Classification A61K 38/46 (2006.01.01); C12N 9/22 (2006.01.01); C12N 15/10 (2006.01.01); C12N 15/113 (2010.01.01)
(19)CountryUS
(41)Date of publication of the application2019.03.31
(49)Date of publication of the translation of the validated European patent specification2024.07.31
(30)Priority201662324024 P, 2016.04.18, US; 201662382522 P, 2016.09.01, US; 201662429428 P, 2016.12.02, US
(74)Patent attorney(Procedură) SOCOLOVA Sofia, Str. Drumul Viilor nr. 42, bloc 3, ap. 60, MD-2021, Chişinău, Republica Moldova
(86)International applicationPCT/IB2017/000577, 2017.04.18
(87)International publicationWO 2017/182881, 2017.10.26
Up
/Inventions/details/3445388